PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



(51) International Patent Classification ⁶ :	A1	(11) International Publication Number: WO 96/36986		
H01J 49/04, C12Q 1/00, G01N 33/48		(43) International Publication Date: 21 November 1996 (21.11.96		
21) International Application Number: PCT/US 22) International Filing Date: 17 May 1996 (ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
30) Priority Data: 08/446,055 08/447,175 19 May 1995 (19.05.95) 19 May 1995 (19.05.95)		Published With international search report. IS Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt amendments.		
 71) Applicant: PERSEPTIVE BIOSYSTEMS, INC. [US/Old Connecticut Path, Framingham, MA 01701 (U 72) Inventors: PATTERSON, Dale, H.; Apartment J, 38 E Drive, Nashua, NH 03062 (US). TARR, George 	JS). Bay Rid	ge		
Essex Street, S. Hamilton, MA 01982 (US). (74) Agent: TURANO, Thomas, A.; Testa, Hurwitz & TL.L.P., High Street Tower, 125 High Street, Bos 02110 (US).	Thibeau	ılt,		
(54) Title: METHODS AND APPARATUS FOR SEQUI SPECTROMETRY	ENCIN	IG POLYMERS WITH A STATISTICAL CERTAINTY USING MAS		
(57) Abstract				
differing ratios of hydrolyzing agent to polymer disposed turther involve integrating data obtained from mass spect	upon a rometry softwar	r sequencing polymers using mass spectrometry. The methods involve reaction surface adapted for use with a mass spectrometer. The methods analysis of a plurality of series of hydrolyzed polymer fragments, and therefor. The apparatus involves a mass spectrometer sample holded lapting any mass spectrometer for polymer sequencing.		

WO 96/36986 PCT/US96/07146

- 32 -

Table 1

	1 dole 1							
Peptide	SEQ ID	Sequence	Average Mass	Charge ²	Polarity			
	Nos.							
Sleep Inducing Peptide	1	WAGGDASGE	848.8	-2.0	polar			
Amino Terminal Region of	2	VHLTPVEK	922.1	+0.5	mid			
Hbs β chain³								
Interleukin-1B 163-171	3	VQGEESNDK	1005.0	-2.0	polar			
Fragment ³		•			F			
TRH Precursor	- 4	-KROHPGKR	1006.2	+4.5	very			
Bradykinin	5	RPPGPSPFR	1061.2	+2.0	mid			
Lutenizing Hormone	6	pyro.EHWSYGLRPG.amide	1182.3	+1.5	mid			
Releasing Hormone ³								
Physalaemin	7	pyro.EADPNKFYGLM.amide	1265.4	0	mid			
Angiotensin 1	8	DRVYIHPFHL	1295.5	+1.0	non			
Renin Inhibitor	9	PHPFHFFVYK	1318.5	+2.0	non			
Kassinin	10	DVPKSDQFVGLM_amide	1334,5	-2.0	non			
Substance P	11	RPKPQQFFGLM.amide	1347.6	+3.0	mid			
T-Antigen Homolog	12	CGYGPKKKRKVGG	1377.7	+5.0	polar			
Osteocalcin 7-19 Fragment	13	GAPVPYPDPLEPR	1407.6	-1.0	mid			
Fibrinopeptide A	14	ADSGEGDFLAEGGGVR	1536.6	-3.0	mid			
Thymopoietin II 29-41	15	GEQRKDVYVQLYL	1610.8	0	polar			
Fragment					-			
Bombesin	16	pyro.EQRLGNQW(AVGH)LM.amide	1619.9	+1.5	mid			
ACTH 11-24 Fragment	17	KPVGKKRRPVKVYP	1652.1	+6.0	mid			
α-Melanocyte Stimulating	18	acetyLSTSMEHFRWGKPV.	1664.9	+1.5	mid			
Hormone		amide						
Angiotensinogen 1-14	19	DRVYIHPFHLLVYS	1759.0	+1.0	non			
Fragment								
Angiogenin	20	ENGLPYHLDQSI(FR)R	1781.0	+0.5	mid			
Glucagon	21	HSQDSRRAQDFVQW(LMN)T	3482.8	+1.0	polar			
ACTH7-38 Fragment	22	FRWRRPVKVYPNGAEDESAEAF PLE	3659.15	+2.0	polar			
		I IAD						

¹ calculated

5

10

15

Listed in Table 1 are the peptides that have been digested and analyzed using this novel on-plate strategy. These peptides were selected to represent peptides of varying amino acid composition, size (up to MW = 3659.15), charge and polarity. The bolded amino acids indicate that a peak representing the loss of that residue was observed in one or more of the MALDI spectra taken across the row of digestions. In order to be able to identify a residue, the peak representing the loss of that amino acid and the preceding amino acid must be present. The residues that are enclosed in parenthesis are those for which the sequence order could not be deduced. Overall, CPY offered some sequence information from the C-terminus for most of the peptides digested, lending no sequence information in only three of the 22 cases. In two of these three cases, the C-terminus was a lysine followed by an acidic residue at the penultimate position. CPY has been reported to possess reduced activity towards basic residues at the C-terminus, and the presence of the neighboring acidic residue seems to further reduce its activity. In the case of the lutenizing hormone releasing hormone (LH-RH), the C-terminal amidated glycine followed by proline at the penultimate position inhibited CPY activity which agrees with reports of CPY slowing at both proline and glycine residues (Hayashi et al. (1975) J. Biochem. 77:69-79:

² at pH 6.5

³ no sequence information was obtained

```
- 48 -
 (2) INFORMATION FOR SEQ ID NO:11:
      (i) SEQUENCE CHARACTERISTICS:
           (A) LENGTH: 11 amino acids
           (B) TYPE: amino acid
           (C) STRANDEDNESS: single
           (D) TOPOLOGY: linear
    (ii) MOLECULE TYPE: peptide -----
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
    Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met
     1
(2) INFORMATION FOR SEQ ID NO:12:
     (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 13 amino acids
          (B) TYPE: amino acid
          (C) STRANDEDNESS: single
          (D) TOPOLOGY: linear
    (ii) MOLECULE TYPE: peptide
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
     Cys Gly Tyr Gly Pro Lys Lys Lys Arg Lys Val Gly Gly
     1
                     5
(2) INFORMATION FOR SEQ ID NO:13:
     (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 13 amino acids
          (B) TYPE: amino acid
          (C) STRANDEDNESS: single
          (D) TOPOLOGY: linear
    (ii) MOLECULE TYPE: peptide
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
    Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu Glu Pro Arg
    1
                    5
                                        10
(2) INFORMATION FOR SEQ ID NO:14:
     (i) SEQUENCE CHARACTERISTICS:
```

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide

WO 96/36986 PCT/US96/07146

			- 49 -						٠
	(xi)	SEQUENCE DESCRIPTION: SEQ	ID NO:	14:					
	Ala A	Asp Ser Gly Glu Gly Asp Phe	Leu Al	a Gl	u Gly	Gly	Gly	Val	Arq
	1	5	10		_	_	-	15	
(2)	INFO	PRMATION FOR SEQ ID NO:15:							
		SEQUENCE CHARACTERISTICS:							
		(A)_ LENGTH: 13 amino acid	is						
		(B) TYPE: amino acid						_	
		(C) STRANDEDNESS: single							
		(D) TOPOLOGY: linear							
	(ii)	MOLECULE TYPE: peptide							
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:								
	Gly	Glu Gln Arg Lys Asp Val Ty	r Val (ln 1	Leu T	yr Le	eu		
	1	5	1	.0	•	-			
(2)	INFO	RMATION FOR SEQ ID NO:16:							
	(i)	SEQUENCE CHARACTERISTICS:							
		(A) LENGTH: 14 amino acid	ls						
		(B) TYPE: amino acid							
		(C) STRANDEDNESS: single							
		(D) TOPOLOGY: linear							
		MOLECULE TYPE: peptide							
	(xi)	SEQUENCE DESCRIPTION: SEQ	ID NO:1	6:					
	Glu	Gln Arg Leu Gly Asn Gln Tr	p Ala V	al G	Sly Hi	is Le	u Met		
	1	5	1	0					
(2)	INFO	RMATION FOR SEQ ID NO:17:							
	(i)	SEQUENCE CHARACTERISTICS:							
		(A) LENGTH: 14 amino acid	s						
		(B) TYPE: amino acid				-			
		(C) STRANDEDNESS: single							
		(D) TOPOLOGY: linear							
	(ii)	MOLECULE TYPE: peptide							
	(xi)	SEQUENCE DESCRIPTION: SEQ	ID NO:1	7:					
	Lys	Pro Val Gly Lys Lys Arg Arg	g Pro V	al L	ys Va	l Ty	r Pro		
	1	5	1	0					
(2)	INFO	RMATION FOR SEQ ID NO:18:	•						

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids